CN1116104C - 可规模化的通过干燥保存生物活性物质的方法 - Google Patents
可规模化的通过干燥保存生物活性物质的方法 Download PDFInfo
- Publication number
- CN1116104C CN1116104C CN97196422A CN97196422A CN1116104C CN 1116104 C CN1116104 C CN 1116104C CN 97196422 A CN97196422 A CN 97196422A CN 97196422 A CN97196422 A CN 97196422A CN 1116104 C CN1116104 C CN 1116104C
- Authority
- CN
- China
- Prior art keywords
- foam
- suspension
- solution
- dispersion liquid
- boiling
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000006260 foam Substances 0.000 title claims abstract description 56
- 238000004321 preservation Methods 0.000 title description 10
- 230000015572 biosynthetic process Effects 0.000 title description 4
- 238000000034 method Methods 0.000 claims abstract description 53
- 239000000243 solution Substances 0.000 claims abstract description 31
- 239000000725 suspension Substances 0.000 claims abstract description 28
- 238000009835 boiling Methods 0.000 claims abstract description 25
- 239000007788 liquid Substances 0.000 claims abstract description 23
- 238000001035 drying Methods 0.000 claims abstract description 19
- 239000006185 dispersion Substances 0.000 claims abstract description 16
- 239000002904 solvent Substances 0.000 claims abstract description 9
- 230000036571 hydration Effects 0.000 claims description 20
- 238000006703 hydration reaction Methods 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 8
- 238000001704 evaporation Methods 0.000 claims description 7
- 230000008020 evaporation Effects 0.000 claims description 7
- 230000002706 hydrostatic effect Effects 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 5
- 239000003223 protective agent Substances 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 3
- 230000009471 action Effects 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 235000014633 carbohydrates Nutrition 0.000 claims description 2
- 239000002577 cryoprotective agent Substances 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims description 2
- 230000008014 freezing Effects 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 230000000630 rising effect Effects 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims 1
- 125000000185 sucrose group Chemical group 0.000 claims 1
- 238000004017 vitrification Methods 0.000 claims 1
- 230000008569 process Effects 0.000 abstract description 13
- 239000000463 material Substances 0.000 abstract description 7
- 239000012530 fluid Substances 0.000 abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 6
- 239000000758 substrate Substances 0.000 abstract description 4
- 239000000839 emulsion Substances 0.000 abstract description 2
- 239000011149 active material Substances 0.000 abstract 1
- 238000005187 foaming Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 18
- 230000000694 effects Effects 0.000 description 7
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 101710088194 Dehydrogenase Proteins 0.000 description 4
- ODBLHEXUDAPZAU-FONMRSAGSA-N Isocitric acid Natural products OC(=O)[C@@H](O)[C@H](C(O)=O)CC(O)=O ODBLHEXUDAPZAU-FONMRSAGSA-N 0.000 description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 4
- ODBLHEXUDAPZAU-UHFFFAOYSA-N threo-D-isocitric acid Natural products OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000009477 glass transition Effects 0.000 description 3
- -1 isocitric acid ester Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- XJLXINKUBYWONI-NNYOXOHSSA-O NADP(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-O 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000005204 segregation Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/04—Preserving or maintaining viable microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S516/00—Colloid systems and wetting agents; subcombinations thereof; processes of
- Y10S516/924—Significant dispersive or manipulative operation or step in making or stabilizing colloid system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2984—Microcapsule with fluid core [includes liposome]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/107497—Preparation composition [e.g., lysing or precipitation, etc.]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/108331—Preservative, buffer, anticoagulant or diluent
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Manufacture Of Porous Articles, And Recovery And Treatment Of Waste Products (AREA)
Abstract
一种通过在待脱水流体物质中形成稳定泡沫来保存敏感的生物分散液、悬浮液、乳液和溶液的方法，该方法既有助于干燥流体中一种或多种生物活性底物，又有助于制备易分开的、适用于进一步商业用途的干燥产物。稳定泡沫是这样形成的：对生物液体抽真空，使其在远低于100℃的温度下“沸腾”。换句话说，将减小的压力施用于生物活性物溶液或悬浮液，使溶液或悬浮液在沸腾时起泡，产生稳定的开腔或闭腔泡沫。在沸腾前，生物物质的比活可用常规浓缩技术(如蒸发、冷冻干燥和膜分离技术)来提高。
Description
发明领域
本发明涉及敏感的生物活性溶质(例如酶、蛋白质、病毒、血清、疫苗、脂质体和细胞悬浮液)以及其悬浮液、乳液和分散液的保存方法。
发明背景
生物活性物质的长期保存对我们来说是一种独特的挑战，因为生物活性物质是我们这个星球上最脆弱的、最易受环境影响的结构(这是它的本质特点)。当然，也有极少数水合物是稳定的，它们能被分离纯化并储藏在室温溶液中较长时间。
从商业和实践的角度来看，以干形式储藏生物活性物质具有许多优点。成功干燥的试剂、物质和组织的重量减少，保存所需的空间减少，但是它们的保存期限却增加。干物质的室温保存比低温保存方案及其费用更经济。
目前生产干的生物活性物质的方法主要包括冷冻干燥、喷雾干燥(参见美国专利No.5,563,318，该专利涉及喷雾干燥的一种变化方案)和流化床干燥，和对液相的小液滴或薄膜进行简单的蒸发干燥。降温保存方法可能有脱水作用，它包括冷冻干燥和/或深低温冷冻。
在生物活性物质经蜕变(transmute)干燥但仍可恢复生物活性形式的许多过程中，特别存在的问题始终是简单的空气干燥或真空干燥步骤很难放大。干燥是扩散限制型过程，因此对于超过10微升的水分含量来说，水分的除去就变得更加复杂，这是一点；而且待干燥的底物越大，其中心部份的有效干燥就越困难。干燥时间与水的扩散系数成反比，与样品大小的平方成正比。我们总不能老是求助于喷雾干燥技术，因为该技术中的一些具有典型的高温对柔弱的生物活性物质有破坏作用。而且，用已知的干燥方法来制备干燥的物质有时会产生稠密的、难溶的团块，这些团块在大规模(full-scale)商业性生物和药物应用中不能很好地作进一步处理。
因此，需要有一种通过干燥来保存敏感生物活性物质的可放大的方法。
发明概述
为了满足这一需求，本发明涉及一种通过从待干燥流体物质形成稳定泡沫来保存敏感的生物悬浮液和溶液的方法，这种方法既有助于流体中一种或多种生物活性底物的干燥，又有助于制得适用于进一步商业用途的易溶的干燥产物。稳定的泡沫是这样形成的：对浓缩的液体抽真空，使其在在远低于100℃的温度下“沸腾”。换句话说，使生物活性物溶液或悬浮液受减压作用，使它们在沸腾过程中产生泡沫，在起泡过程中进一步除去水分，最终产生稳定的开腔或闭腔泡沫。这些泡沫很容易通过切割、研磨或其它分隔方法来细分，而且起泡作用本身通过使液体蒸发面积或其它溶剂放散(evolutin)面积最大化而增强了水分的除去。
本发明的一个较佳实施方案公开了一种通过干燥来保存生物活性物质的方法。方法包括下列步骤：使含有生物活性剂的溶液、分散液或悬浮液受相应于低于24托的压力的真空作用，其中该真空度足以使溶液、分散液或悬浮液沸腾，从而使沸腾的溶液、分散液或悬浮液在沸腾期间干燥产生物理上稳定的泡沫。
在另一较佳实施方案中，所述流体静压在0到7.6托之间。
在另一较佳实施方案中，在使所述溶液、分散液或悬浮液沸腾的步骤之前，通过在压力高于7.6托的真空度下蒸发、从部分冷冻状态蒸发(即冷冻干燥)，或用反向渗透或其它膜技术，以减少溶液、分散液或悬浮液沸腾的时间。
在另一较佳实施方案中，通过在升高温度下对所述稳定泡沫施加真空或干空气中的一种来进行二次干燥。
根据本发明的另一实施方案，通过沸腾产生物理上稳定的泡沫来保存生物活性物质的方法还包括使泡沫与合适溶剂接触保存并使所述稳定泡沫重新水合的步骤。重新水合可在高于重新水合前泡沫保存温度的温度下进行。或者，重新水合前的泡沫保存温度至少和环境温度一样高。或者，重新水合可在等于或低于泡沫保存温度的温度下进行。在另一变化方案中，重新水合前的泡沫保存温度低于或等于环境温度。在另一个形式中，重新水合所用溶剂是包括低温保护剂的水性溶液。
发明详述
本发明是一种通过从待干燥流体物质形成稳定泡沫来保存敏感的生物分散液、悬浮液和溶液的方法，这种方法既有助于干燥流体中一种或多种生物活性底物，又有助于制得适用于进一步商业用途的容易细分的干燥产物。稳定的泡沫是这样形成的：进一步对生物液体抽真空，使其在远低于100℃的温度下“沸腾”。换句话说，使生物活性物溶液或悬浮液受减压作用，使溶液或悬浮液在沸腾过程中产生泡沫，产生稳定的开腔或闭腔泡沫。样品中的沸腾在室温或更低温度下进行，以避免生物活性物质受热损伤。如果真空室中的流体静压低于24托(这是25℃水上的平衡蒸汽压)，施加真空使得生物液体在室温(通常为25℃)或更低温度下沸腾。
在沸腾前，生物物质的比活可采用常规浓缩技术(如蒸发、冷冻干燥和膜分离技术)来提高。
在形成泡沫后，可在升高的温度下在真空下对泡沫进行进一步(“第二次”)干燥，干燥时间为达到预定的玻璃转化温度所需的时间。这些泡沫很容易通过切割、研磨或其它分隔方法来细分，而且起泡作用本身通过使液体蒸发面积最大化而增强了水分的除去。(通常，待干燥物质的溶剂部分是水性的；然而，应当理解本发明适用于各种类型的溶液和悬浮液，包括那些含有非水性溶剂或这些溶剂的混合物的溶液和悬浮液)。
适用于该真空-沸腾-泡沫-形成革新方法的生物液体实际上是无限的。确实何溶液或悬浮液均可用本发明的真空沸腾方法来脱水，但是该方法在保存敏感的生物物质方面有明显的优点(即，由于较低的干燥温度而避免了破坏)。对于掺入了保护剂以及基本上任何类型溶剂的溶液，当它受低于大气压作用并在沸腾过程中产生泡沫时，它受的干燥作用会增强。保护剂可以包括(没有限制)：糖(包括蔗糖)、碳水化合物、多糖、水溶性聚合物、肽或蛋白质等，只要保护剂能增强生物活性物质经受干燥和保存的能力，而且不干扰特定的生物活性。
一旦理解了本发明中干燥过程与减压沸腾的结合，就可以看出在最简单的实例中本发明的装置是一种真空泵和温度控制干燥器的新组合装置。这一组合的其它任选特征包括：测定温度和热流控制的传感器，根据从这些及其它传感器收集的数据来计算其它过程参数的微处理器等。这种装置能够实现新的用于干燥的二维的真空和温度的设置方案。
在本发明的一个重要实例中，泡沫的形成包括两个步骤：(a)通过真空下沸腾使含有生物活性剂的溶液或分散液充分脱水，形成稳定的不会被破坏的泡沫，和(b)随后将泡沫二次干燥至泡沫稳定并且不会在保存时被破坏。如果泡沫中物质的玻璃转化温度高于保存温度，泡沫在长期保存期间不会破裂。
如上所述，本发明提供了一种可改变规模的保存敏感的生物活性物质(蛋白质、酶、血清、疫苗、病毒、脂质体和细胞悬浮液)方法，该方法采用了独特的工程化干燥方法。采用这种方法，就可以用水或水性溶液使样品重新水合，以使该过程逆转并恢复成原始的生物活性。该方法适用于保存药物、流体或实际上其它任何生物活性产物或溶质。
在本发明的方法中，相当大量的生物活性液体(溶液或悬浮液)可通过真空下沸腾而脱水形成稳定的泡沫，因为沸腾是湍流的可规模化的过程。泡沫的形成是一个动态的过程，它取决于形成泡沫过程中温度和真空度的改变速度，以及含有生物活性物质的溶液或悬浮液的初始浓度和组成。根据本发明制得的泡沫可整个保存或可细分或研磨，当要使用它们时，为了要重新恢复它们原来的生物活性，泡沫只需进行重新水合。通过加入表面活性剂或其它合成或生物聚合物，可进一步增强泡沫的稳定性，只要那些添加剂不干扰打算转化成干形式的溶质的生物活性。可在升高的温度下对干的泡沫进行二次干燥，随后冷却至低于玻璃转化温度的保存温度，以确保保存时的泡沫稳定性。在恒定的流体静压下，玻璃态只能通过冷却获得，因为它不取决于样品中的扩散速度。单单地干燥不能获得玻璃态，因为它是缓慢的扩散限制过程。
下列实施例用来描述本发明的实施方案，其中样品在沸腾经蒸发浓缩。尽管这些实施例说明敏感的生物物质可通过形成泡沫来保存，但是本文公开的各个实施方案绝不应被理解为局限于下列工作例中描述的具体过程。
实施例1
使含有59.4单位活性/毫升的50％异柠檬酸甘油酯脱氢酶水溶液(购自SigmaChemical Co.)在0.1M Tris HCl缓冲液(pH＝7.4)中透析5小时。在透析后，0.1M TrisHCl溶液中异柠檬酸酯脱氢酶的活性为26±1.8单位/毫升。活性随着透析时稀释而引起的酶浓度的降低而降低。
将100微升的混合物放在1.5毫升塑料管中并在室温下干燥进行保存，该混合物含有50微升50％(重量)的蔗糖溶液和50微升在0.1M Tris HCl缓冲液(pH7.4)中的异柠檬酸酯脱氢酶悬浮液。首先，使样品在低真空度(流体静压P＝0.2大气压)下干燥4小时。第二，使样品在高真空度(P＜0.01大气压)下沸腾4小时。在这一步中，试管内形成了稳定的干泡沫。第三，使样品在真空、室温下，在DRIERITE上保存8天。
在保存规定天数后，用500微升水使样品重新水合。含有干泡沫的样品的重新水合是容易的，它可在几秒种内完成。通过在340nm用分光光度计测定还原NADP的能力来测定重建样品的活性。反应混合物包括：2毫升0.1M Tris HCl缓冲液，pH＝7.4；10微升0.5％(重量)NADP+；10微升10mM MnSO4溶液；10微升50mM 1-异柠檬酸酯；以及10微升异柠檬酸酯脱氢酶溶液。活性为2.6±0.2单位/毫升，这意味着在室温下干燥和随后的保存中活性没有损失。
实施例2
将100微升的混合物放在1.5毫升塑料管中并在室温下干燥进行保存，该混合物含有50微升50％(重量)的蔗糖溶液和50微升冰晶核细菌悬浮液(由GenencorInternational，Inc.提供)。首先，使样品在低真空度(流体静压P＝0.2大气压)下干燥4小时。第二，使样品在高真空度(P＜0.01大气压)下沸腾4小时。在真空下沸腾后，试管内形成了稳定的干泡沫。第三，使样品在真空、室温下在DRIERITE上保存8天。在保存8天后，用500微升水使样品重新水合。含有干泡沫的样品的重新水合是容易的，它可在几秒钟内完成。然后测定样品的冰成核活性与对照样品比较。我们发现用本发明方法保存的样品每1000个细菌的冰成核活性与对照样品没有显著区别。
尽管本发明已参照上述特定实施例和细节进行了描述，但是本发明的范围只能取决于在附加的权利要求中所提出的陈述。
Claims (14)
1.一种通过干燥来保存生物活性物质的方法，方法包括下列步骤：使含有生物活性剂的溶液、分散液或悬浮液受相应于低于24托的压力的真空作用，该真空度足以使所述溶液、分散液或悬浮液引起沸腾，从而使得所述沸腾的溶液、分散液或悬浮液在沸腾期间干燥产生物理上稳定的泡沫。
2.根据权利要求1所述的方法，其中所述流体静压在0到7.6托之间。
3.根据权利要求1所述的方法，其中在使所述溶液、分散液或悬浮液沸腾的步骤之前，通过在压力高于7.6托的真空度下蒸发、从部分冷冻状态蒸发即冷冻干燥，或用反向渗透或其它膜技术，以减少溶液、分散液或悬浮液沸腾的时间。
4.根据权利要求1所述的方法，其中通过在升高温度下对所述稳定泡沫施加真空或干空气中的一种来进行二次干燥。
5.根据权利要求4所述的方法，其中在二次干燥步骤后将样品冷却到温度低于干泡沫的玻璃化温度。
6.根据权利要求5所述的方法，其中在施加所述高真空度之前先在所述溶液、分散液或悬浮液中加入表面活性剂，使在二次干燥时增加泡沫稳定性。
7.根据权利要求6所述的方法，其中所述溶液、分散液或悬浮液含有选自糖、碳水化合物、多糖、聚合物、肽、蛋白质及其混合物的保护剂，其中所述保护剂增强了生物活性物质经受干燥和保存的能力。
8.根据权利要求1所述的方法，其中所述方法还包括通过所述泡沫与合适溶剂接触来使所述稳定泡沫重新水合。
9.根据权利要求8所述的方法，其中所述重新水合是在高于重新水合前泡沫保存温度的温度下进行。
10.根据权利要求9所述的方法，其中重新水合前的泡沫保存温度至少和环境温度一样高。
11.根据权利要求8所述的方法，其中所述重新水合在等于或低于重新水合前泡沫保存温度的温度下进行。
12.根据权利要求8所述的方法，其中重新水合前的泡沫保存温度低于或等于环境温度。
13.根据权利要求8所述的方法，其中所述溶剂是包括低温保护剂的水性溶液。
14.根据权利要求7所述的方法，其中所述糖是蔗糖。
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2179696P | 1996-07-15 | 1996-07-15 | |
| US60/021,796 | 1996-07-15 | ||
| US08/785,473 US5766520A (en) | 1996-07-15 | 1997-01-17 | Preservation by foam formation |
| US08/785,473 | 1997-01-17 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1226842A CN1226842A (zh) | 1999-08-25 |
| CN1116104C true CN1116104C (zh) | 2003-07-30 |
Family
ID=26695104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN97196422A Expired - Fee Related CN1116104C (zh) | 1996-07-15 | 1997-07-14 | 可规模化的通过干燥保存生物活性物质的方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US5766520A (zh) |
| EP (1) | EP0914202A4 (zh) |
| JP (1) | JP2000515856A (zh) |
| KR (1) | KR100457748B1 (zh) |
| CN (1) | CN1116104C (zh) |
| AU (1) | AU714328B2 (zh) |
| BR (1) | BR9711808A (zh) |
| CA (1) | CA2260233A1 (zh) |
| CZ (1) | CZ7999A3 (zh) |
| DE (1) | DE914202T1 (zh) |
| EA (1) | EA001138B1 (zh) |
| HU (1) | HUP9903917A3 (zh) |
| IL (1) | IL127971A (zh) |
| NO (1) | NO990158D0 (zh) |
| NZ (1) | NZ333738A (zh) |
| PL (1) | PL331174A1 (zh) |
| TR (1) | TR199900127T2 (zh) |
| WO (1) | WO1998002240A1 (zh) |
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ257212A (en) * | 1992-09-29 | 1996-11-26 | Inhale Therapeutic Syst | Parathyroid hormone formulations comprising a biologically active n-terminal fragment of the hormone |
| US20030113273A1 (en) * | 1996-06-17 | 2003-06-19 | Patton John S. | Methods and compositions for pulmonary delivery of insulin |
| US6290991B1 (en) | 1994-12-02 | 2001-09-18 | Quandrant Holdings Cambridge Limited | Solid dose delivery vehicle and methods of making same |
| JPH10508744A (ja) | 1994-09-22 | 1998-09-02 | クオドラント ホールディングス ケンブリッジ リミテッド | 運動競技の間の水分補給および栄養摂取の用途のための組成物ならびにその製造法 |
| US6964771B1 (en) * | 1995-06-07 | 2005-11-15 | Elan Drug Delivery Limited | Method for stably incorporating substances within dry, foamed glass matrices |
| US6509146B1 (en) | 1996-05-29 | 2003-01-21 | Universal Preservation Technologies, Inc. | Scalable long-term shelf preservation of sensitive biological solutions and suspensions |
| US6468782B1 (en) * | 1996-12-05 | 2002-10-22 | Quadrant Healthcare (Uk) Limited | Methods of preserving prokaryotic cells and compositions obtained thereby |
| GB9705588D0 (en) | 1997-03-18 | 1997-05-07 | Anglia Research Foundation | Stable particle in liquid formulations |
| US20060116330A1 (en) * | 1997-07-08 | 2006-06-01 | The Iams Company | Methods of mimicking the metabolic effects of caloric restriction by administration of mannoheptulose |
| US8563522B2 (en) * | 1997-07-08 | 2013-10-22 | The Iams Company | Method of maintaining and/or attenuating a decline in quality of life |
| US20020035071A1 (en) * | 1997-07-08 | 2002-03-21 | Josef Pitha | Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites |
| US6565885B1 (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
| US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
| DE69735600T2 (de) * | 1997-11-26 | 2007-01-25 | Universal Preservation Technologies, Inc., San Diego | Konservierung empfindlicher biologischer proben durch verglasung |
| US6306345B1 (en) * | 1998-05-06 | 2001-10-23 | Universal Preservation Technologies, Inc. | Industrial scale barrier technology for preservation of sensitive biological materials at ambient temperatures |
| US6214054B1 (en) | 1998-09-21 | 2001-04-10 | Edwards Lifesciences Corporation | Method for fixation of biological tissues having mitigated propensity for post-implantation calcification and thrombosis and bioprosthetic devices prepared thereby |
| CA2360112A1 (en) | 1999-01-05 | 2000-07-13 | Victor Bronshtein | Vacuum control system for foam drying apparatus |
| DK1175486T3 (da) * | 1999-05-04 | 2007-10-29 | Anhydro Ltd | Fremgangsmåde til konservering af virus og mycoplasma |
| US6692695B1 (en) | 1999-05-06 | 2004-02-17 | Quadrant Drug Delivery Limited | Industrial scale barrier technology for preservation of sensitive biological materials |
| CA2382061A1 (en) * | 1999-08-19 | 2001-02-22 | Victor Bronshtein | Preservation of bacterial cells at ambient temperatures |
| WO2001037804A2 (en) * | 1999-11-22 | 2001-05-31 | Universal Preservation Technologies, Inc. | Preservation and formulation of bioactive materials |
| US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
| DK1280520T4 (en) | 2000-05-10 | 2018-06-25 | Novartis Ag | Phospholipid based powders for drug delivery |
| US8404217B2 (en) | 2000-05-10 | 2013-03-26 | Novartis Ag | Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use |
| WO2001094867A1 (en) | 2000-06-07 | 2001-12-13 | Universal Preservation Technologies, Inc. | Industrial scale barrier technology for preservation of sensitive biological materials |
| HU229550B1 (en) * | 2000-06-27 | 2014-01-28 | Hoffmann La Roche | Method for preparing compositions |
| US6537666B1 (en) * | 2000-10-23 | 2003-03-25 | Universal Preservation Technologies, Inc. | Methods of forming a humidity barrier for the ambient temperature preservation of sensitive biologicals |
| US6872357B1 (en) * | 2000-11-22 | 2005-03-29 | Quadrant Drug Delivery Limited | Formulation of preservation mixtures containing sensitive biologicals to be stabilized for ambient temperature storage by drying |
| US7153472B1 (en) * | 2000-11-22 | 2006-12-26 | Quadrant Drug Delivery Limited | Preservation and formulation of bioactive materials for storage and delivery in hydrophobic carriers |
| AU2002305461A1 (en) * | 2001-05-07 | 2002-11-18 | Universal Preservation Technologies, Inc. | Preservation of competent cells at ambient temperatures |
| US6884866B2 (en) * | 2001-10-19 | 2005-04-26 | Avant Immunotherapeutics, Inc. | Bulk drying and the effects of inducing bubble nucleation |
| EP1458360B1 (en) | 2001-12-19 | 2011-05-11 | Novartis AG | Pulmonary delivery of aminoglycosides |
| US6878168B2 (en) | 2002-01-03 | 2005-04-12 | Edwards Lifesciences Corporation | Treatment of bioprosthetic tissues to mitigate post implantation calcification |
| CA2482448C (en) * | 2002-04-11 | 2014-07-08 | Medimmune Vaccines, Inc. | Preservation of bioactive materials by freeze dried foam |
| US7927858B2 (en) | 2002-11-01 | 2011-04-19 | Glaxosmithkline Biologicals, S.A. | Drying process |
| US20050100559A1 (en) * | 2003-11-07 | 2005-05-12 | The Procter & Gamble Company | Stabilized compositions comprising a probiotic |
| US20050100636A1 (en) * | 2003-11-10 | 2005-05-12 | Megan Botteri | [A Low-Calorie Sports Drink For Physically Active Women That is Fortified with Iron, Calcium and Essential Vitamins for Use in Rehydration and Replacing Electrolytes Lost During Periods of Physical Activity] |
| US8894991B2 (en) * | 2003-12-19 | 2014-11-25 | The Iams Company | Canine probiotic Lactobacilli |
| US8877178B2 (en) * | 2003-12-19 | 2014-11-04 | The Iams Company | Methods of use of probiotic bifidobacteria for companion animals |
| US20050152884A1 (en) * | 2003-12-19 | 2005-07-14 | The Procter & Gamble Company | Canine probiotic Bifidobacteria globosum |
| US7785635B1 (en) | 2003-12-19 | 2010-08-31 | The Procter & Gamble Company | Methods of use of probiotic lactobacilli for companion animals |
| US20050158294A1 (en) * | 2003-12-19 | 2005-07-21 | The Procter & Gamble Company | Canine probiotic Bifidobacteria pseudolongum |
| US9744227B2 (en) | 2004-06-02 | 2017-08-29 | Universal Stabilization Technologies, Inc. | Compositions containing ambient-temperature stable, inactivated but therapeutically active biopharmaceuticals and methods for formulation thereof |
| CA2569276C (en) | 2004-06-02 | 2018-01-23 | Victor Bronshtein | Preservation by vaporization |
| JP2007277094A (ja) * | 2004-06-29 | 2007-10-25 | Chemo Sero Therapeut Res Inst | 改変ダニ主要アレルゲン含有医薬組成物 |
| CA2571232C (en) * | 2004-07-30 | 2010-02-16 | The University Of British Columbia | Method for producing hydrocolloid foams |
| AR052472A1 (es) * | 2005-05-31 | 2007-03-21 | Iams Company | Lactobacilos probioticos para felinos |
| EP1885383B1 (en) * | 2005-05-31 | 2016-09-21 | IAMS Europe B.V. | Feline probiotic bifidobacteria |
| US8968721B2 (en) | 2005-12-28 | 2015-03-03 | Advanced Bionutrition Corporation | Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same |
| WO2007079147A2 (en) | 2005-12-28 | 2007-07-12 | Advanced Bionutrition Corporation | A delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same |
| US9453675B2 (en) * | 2006-02-10 | 2016-09-27 | Sp Industries, Inc. | Method of inducing nucleation of a material |
| EP2077718B2 (en) | 2006-10-27 | 2022-03-09 | Edwards Lifesciences Corporation | Biological tissue for surgical implantation |
| CA2673120C (en) | 2006-12-18 | 2012-08-07 | Advanced Bionutrition Corporation | A dry food product containing live probiotic |
| WO2008093303A2 (en) | 2007-02-01 | 2008-08-07 | The Iams Company | Method for decreasing inflammation and stress in a mammal using glucose antimetaboltes, avocado or avocado extracts |
| US8617576B2 (en) * | 2007-05-18 | 2013-12-31 | Medimmune, Llc | Preservation of bioactive materials by freeze dried foam |
| US9101691B2 (en) * | 2007-06-11 | 2015-08-11 | Edwards Lifesciences Corporation | Methods for pre-stressing and capping bioprosthetic tissue |
| JP2010534622A (ja) | 2007-07-26 | 2010-11-11 | サノフィ パストゥール リミテッド | 抗原−アジュバント組成物および方法 |
| CA2699120C (en) * | 2007-09-13 | 2014-07-08 | Enwave Corporation | Apparatus and method for dehydrating biological materials |
| US8357387B2 (en) * | 2007-12-21 | 2013-01-22 | Edwards Lifesciences Corporation | Capping bioprosthetic tissue to reduce calcification |
| US9771199B2 (en) | 2008-07-07 | 2017-09-26 | Mars, Incorporated | Probiotic supplement, process for making, and packaging |
| CA2736317C (en) | 2008-09-12 | 2015-06-16 | Enwave Corporation | Apparatus and method for dehydrating biological materials with freezing and microwaving |
| EP3266448B1 (en) | 2009-03-27 | 2022-02-16 | Intervet International B.V. | Microparticulated vaccines for the oral or nasal vaccination and boostering of animals including fish |
| CN102459568A (zh) | 2009-05-26 | 2012-05-16 | 先进生物营养公司 | 包含生物活性微生物和/或生物活性材料的稳定干粉组合物及其制造方法 |
| US10104903B2 (en) | 2009-07-31 | 2018-10-23 | Mars, Incorporated | Animal food and its appearance |
| US20110064723A1 (en) * | 2009-09-14 | 2011-03-17 | Aridis Pharmaceuticals | Formulation for room temperature stabilization of a live attenuated bacterial vaccine |
| US9504750B2 (en) | 2010-01-28 | 2016-11-29 | Advanced Bionutrition Corporation | Stabilizing composition for biological materials |
| SG182317A1 (en) | 2010-01-28 | 2012-08-30 | Advanced Bionutrition Corp | Dry glassy composition comprising a bioactive material |
| EP2549957B1 (en) | 2010-03-23 | 2019-01-30 | Edwards Lifesciences Corporation | Methods of conditioning sheet bioprosthetic tissue |
| US8906601B2 (en) | 2010-06-17 | 2014-12-09 | Edwardss Lifesciences Corporation | Methods for stabilizing a bioprosthetic tissue by chemical modification of antigenic carbohydrates |
| RS57588B1 (sr) * | 2010-08-13 | 2018-11-30 | Advanced Bionutrition Corp | Supstanca za stabilizaciju bioloških materijala za suvo skladištenje |
| US9351829B2 (en) | 2010-11-17 | 2016-05-31 | Edwards Lifesciences Corporation | Double cross-linkage process to enhance post-implantation bioprosthetic tissue durability |
| US10238771B2 (en) | 2012-11-08 | 2019-03-26 | Edwards Lifesciences Corporation | Methods for treating bioprosthetic tissue using a nucleophile/electrophile in a catalytic system |
| PT3003246T (pt) | 2013-05-31 | 2021-02-22 | Victor Bronshtein | Composições poliméricas contendo produtos biofarmacêuticos estáveis à temperatura ambiente e métodos para a formulação dos mesmos |
| US9615922B2 (en) | 2013-09-30 | 2017-04-11 | Edwards Lifesciences Corporation | Method and apparatus for preparing a contoured biological tissue |
| US10959839B2 (en) | 2013-10-08 | 2021-03-30 | Edwards Lifesciences Corporation | Method for directing cellular migration patterns on a biological tissue |
| US9938558B2 (en) | 2015-06-25 | 2018-04-10 | Ascus Biosciences, Inc. | Methods, apparatuses, and systems for analyzing microorganism strains from complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon |
| EP3314007B1 (en) | 2015-06-25 | 2024-01-24 | Native Microbials, Inc. | Methods, apparatuses, and systems for analyzing microorganism strains from complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon |
| US10851399B2 (en) | 2015-06-25 | 2020-12-01 | Native Microbials, Inc. | Methods, apparatuses, and systems for microorganism strain analysis of complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon |
| WO2018126026A1 (en) | 2016-12-28 | 2018-07-05 | Ascus Biosciences, Inc. | Methods, apparatuses, and systems for analyzing complete microorganism strains in complex heterogeneous communities, determining functional relationships and interactions thereof, and identifying and synthesizing bioreactive modificators based thereon |
| AU2016297986B8 (en) | 2015-07-29 | 2020-06-11 | Advanced Bionutrition Corp. | Stable dry probiotic compositions for special dietary uses |
| RU2018140070A (ru) | 2016-04-15 | 2020-05-15 | Аскус Байосайенсиз, Инк. | Способы улучшения сельскохозяйственного производства птицы путем применения микробных консорциумов или их штаммов |
| CN106434840B (zh) * | 2016-12-02 | 2019-08-09 | 北京中检葆泰生物技术有限公司 | 一种用于微生物法定量检测维生素b12的微孔板、其试剂盒及其制备方法 |
| CN110352250A (zh) | 2016-12-28 | 2019-10-18 | 埃斯库斯生物科技股份公司 | 用于通过示踪剂分析法对复杂异质群落进行微生物株系分析、确定其功能关系及相互作用以及合成包括给药微生物群集和接种微生物群集的微生物群集的方法、设备和系统 |
| CN106676161B (zh) * | 2017-01-03 | 2020-01-21 | 北京中检葆泰生物技术有限公司 | 一种用于微生物法定量检测烟酸的微孔板、其试剂盒及其制备方法 |
| CN106676160B (zh) * | 2017-01-03 | 2020-02-21 | 北京中检葆泰生物技术有限公司 | 一种用于微生物法定量检测泛酸的微孔板、其试剂盒及其制备方法 |
| CN106591415B (zh) * | 2017-01-03 | 2019-12-10 | 北京中检葆泰生物技术有限公司 | 一种用于微生物法定量检测生物素的微孔板、其试剂盒及其制备方法 |
| CN106701887B (zh) * | 2017-01-03 | 2020-01-17 | 北京中检葆泰生物技术有限公司 | 一种用于微生物法定量检测叶酸的微孔板、其试剂盒及其制备方法 |
| US10617756B2 (en) | 2017-01-05 | 2020-04-14 | Shimojani, LLC | Drug regimen for treatment of cerebral ischemia |
| WO2018201154A1 (en) * | 2017-04-28 | 2018-11-01 | Universal Stabilization Technologies, Inc. | Antigenic thermostable polio vaccines & related methods |
| CA3062547A1 (en) | 2017-05-31 | 2018-12-06 | Edwards Lifesciences Corporation | Collagen fibers and articles formed therefrom |
| CN111970933A (zh) | 2017-10-18 | 2020-11-20 | 埃斯库斯生物科技股份公司 | 通过施用微生物或其纯化菌株的合成生物集合体来提高禽类产量 |
| CN111491675A (zh) | 2018-01-23 | 2020-08-04 | 爱德华兹生命科学公司 | 用于预拉伸可植入生物相容性材料的方法及其生产的材料和装置 |
| JP7138336B2 (ja) * | 2018-06-29 | 2022-09-16 | 国立大学法人九州工業大学 | 生体由来の水溶性高分子乾燥品の製造方法及びその製造装置 |
| CA3116158A1 (en) | 2018-11-01 | 2020-05-07 | Edwards Lifesciences Corporation | Transcatheter pulmonic regenerative valve |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5271881A (en) * | 1987-09-28 | 1993-12-21 | Redding Bruce K | Apparatus and method for making microcapsules |
| US5409703A (en) * | 1993-06-24 | 1995-04-25 | Carrington Laboratories, Inc. | Dried hydrogel from hydrophilic-hygroscopic polymer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4642903A (en) * | 1985-03-26 | 1987-02-17 | R. P. Scherer Corporation | Freeze-dried foam dosage form |
| DE229810T1 (de) * | 1985-07-09 | 1987-11-05 | Quadrant Bioresources Ltd., Soulbury, Leighton Buzzard, Bedfordshire | Beschuetzung von proteinen und aehnlichem. |
| GB8903593D0 (en) * | 1989-02-16 | 1989-04-05 | Pafra Ltd | Storage of materials |
| US5200399A (en) * | 1990-09-14 | 1993-04-06 | Boyce Thompson Institute For Plant Research, Inc. | Method of protecting biological materials from destructive reactions in the dry state |
| AU659645B2 (en) * | 1991-06-26 | 1995-05-25 | Inhale Therapeutic Systems | Storage of materials |
| US5565318A (en) * | 1994-09-02 | 1996-10-15 | Pharmacia Biotech, Inc. | Room temperature stable reagent semi-spheres |
| AU713599B2 (en) * | 1995-06-07 | 1999-12-09 | Quadrant Drug Delivery Limited | Methods for stably incorporating substances within dry, foamed glass matrices and compositions obtained thereby |
-
1997
- 1997-01-17 US US08/785,473 patent/US5766520A/en not_active Expired - Fee Related
- 1997-07-14 CZ CZ9979A patent/CZ7999A3/cs unknown
- 1997-07-14 EA EA199900268A patent/EA001138B1/ru not_active IP Right Cessation
- 1997-07-14 PL PL97331174A patent/PL331174A1/xx unknown
- 1997-07-14 TR TR1999/00127T patent/TR199900127T2/xx unknown
- 1997-07-14 HU HU9903917A patent/HUP9903917A3/hu not_active Application Discontinuation
- 1997-07-14 CN CN97196422A patent/CN1116104C/zh not_active Expired - Fee Related
- 1997-07-14 NZ NZ333738A patent/NZ333738A/xx unknown
- 1997-07-14 EP EP97933415A patent/EP0914202A4/en not_active Withdrawn
- 1997-07-14 WO PCT/US1997/012156 patent/WO1998002240A1/en not_active Application Discontinuation
- 1997-07-14 IL IL12797197A patent/IL127971A/en not_active IP Right Cessation
- 1997-07-14 JP JP10506201A patent/JP2000515856A/ja not_active Ceased
- 1997-07-14 KR KR10-1999-7000253A patent/KR100457748B1/ko not_active IP Right Cessation
- 1997-07-14 CA CA002260233A patent/CA2260233A1/en not_active Abandoned
- 1997-07-14 AU AU36606/97A patent/AU714328B2/en not_active Ceased
- 1997-07-14 DE DE0914202T patent/DE914202T1/de active Pending
- 1997-07-14 BR BR9711808-7A patent/BR9711808A/pt unknown
-
1999
- 1999-01-14 NO NO990158A patent/NO990158D0/no not_active Application Discontinuation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5271881A (en) * | 1987-09-28 | 1993-12-21 | Redding Bruce K | Apparatus and method for making microcapsules |
| US5409703A (en) * | 1993-06-24 | 1995-04-25 | Carrington Laboratories, Inc. | Dried hydrogel from hydrophilic-hygroscopic polymer |
Also Published As
| Publication number | Publication date |
|---|---|
| EA001138B1 (ru) | 2000-10-30 |
| NO990158L (no) | 1999-01-14 |
| PL331174A1 (en) | 1999-06-21 |
| IL127971A0 (en) | 1999-11-30 |
| EA199900268A1 (ru) | 1999-10-28 |
| NO990158D0 (no) | 1999-01-14 |
| JP2000515856A (ja) | 2000-11-28 |
| CN1226842A (zh) | 1999-08-25 |
| CZ7999A3 (cs) | 1999-11-17 |
| EP0914202A4 (en) | 2004-09-01 |
| US5766520A (en) | 1998-06-16 |
| WO1998002240A1 (en) | 1998-01-22 |
| TR199900127T2 (xx) | 1999-04-21 |
| NZ333738A (en) | 2000-09-29 |
| HUP9903917A2 (hu) | 2000-03-28 |
| CA2260233A1 (en) | 1998-01-22 |
| AU3660697A (en) | 1998-02-09 |
| BR9711808A (pt) | 2000-01-18 |
| KR100457748B1 (ko) | 2004-11-17 |
| DE914202T1 (de) | 2000-02-17 |
| KR20000023779A (ko) | 2000-04-25 |
| IL127971A (en) | 2001-09-13 |
| EP0914202A1 (en) | 1999-05-12 |
| AU714328B2 (en) | 1999-12-23 |
| HUP9903917A3 (en) | 2000-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1116104C (zh) | 可规模化的通过干燥保存生物活性物质的方法 | |
| WO1998002240B1 (en) | Preservation by foam formation | |
| Kasraian et al. | The effect of tertiary butyl alcohol on the resistance of the dry product layer during primary drying | |
| US6509146B1 (en) | Scalable long-term shelf preservation of sensitive biological solutions and suspensions | |
| JP2001524306A (ja) | ガラス化による不安定な生物学的サンプルの保存 | |
| Jin et al. | Nanofibrillar cellulose aerogels | |
| US4925790A (en) | Method of producing products by enzyme-catalyzed reactions in supercritical fluids | |
| AU780602B2 (en) | Preservation of sensitive biological material | |
| US20030022333A1 (en) | Long-term shelf preservation by vitrification | |
| Owen et al. | Isolation and properties of mesosomal membrane fractions from Micrococcus lysodeikticus | |
| CA2360112A1 (en) | Vacuum control system for foam drying apparatus | |
| Record et al. | The survival of Escherichia coli on drying and rehydration | |
| Randolph et al. | Biocatalysis in supercritical fluids | |
| Pitombo et al. | Effect of moisture content on the invertase activity of freeze-dried S. cerevisiae | |
| CN1286725A (zh) | 敏感性生物样品的玻化保质法 | |
| Nussinovitch et al. | Characteristics of enzymatically produced agar-starch sponges | |
| Padmanabhan et al. | Enhanced leaching of product at elevated temperatures: alpha‐amylase produced by Bacillus licheniformis M27 in solid state fermentation system | |
| Boyadzhiev et al. | Extraction of tylosin from its aqueous solutions by Rotating Film-pertraction | |
| US3271875A (en) | Method for stabilizing unstable substances | |
| JP4809536B2 (ja) | ゲルの氷結脱水法 | |
| Baydemir Peşint et al. | Enhanced invertase binding from baker’s yeast via cryogels included boronic acids | |
| Lee et al. | Concentration polarization and shear deactivation of protein during ultrafiltration/diafiltration | |
| MXPA00005123A (en) | Preservation of sensitive biological samples by vitrification | |
| Dennison et al. | Concentration of the extract | |
| NO135922B (zh) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1033871 Country of ref document: HK |
|
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |